prenetics.com (PRE) Company Sales Revenue

The resilience of Prenetics Global (PRE) is based on overcoming the post-pandemic slump and expanding into new niches. The company's sales figures confirm this trend, with the current value standing at 0.14. Growth is driven by investments in preventive oncology and genetics in Asia, while AI-powered robotic sequencers automate DNA analysis, maintaining expert physician control over final diagnoses.

PRE Prenetics: Company Revenue in the range 04/28/2023 - 11/13/2026

Analytical breakdowns for Prenetics Global Limited (PRE)

- stock price and consensus target price:

Quote Chart Prenetics Global Ltd|PRE - Price Target Chart

- market capitalization details:

Market Value Prenetics Global|PRE - Enterprise Value

- balance sheet net asset value indicators:

Net Asset Value per Share Prenetics|PRE - Company Book Value|Capitalization to Book Value Ratio prenetics.com|PRE - Company Total Assets

- debt and solvency information:

- business earnings and investment ratios data:

PRE - Net Income|Expected Net Income Prenetics Global|PRE - P/E Multiple|Forward Price to Earnings Multiple Prenetics Global Ltd|PRE - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prenetics Global|PRE - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Prenetics|PRE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months prenetics.com|PRE - Earnings growth in current year|Earnings growth forecast for next year Prenetics Global

- sales volume and revenue indicators:

PRE - Company Revenue|Company Projected Revenue Prenetics Global Ltd|PRE - Price-to-Revenue Ratio|Future Price to Revenue Prenetics Global

Summary company analysis:Prenetics Global

Daily revenue measures the actual cash inflow rate, allowing for an assessment of the business's real liquidity. The current aggregate sales level of Prenetics Global (PRE) on GURU.Markets confirms stable demand for consumer DNA tests and cancer screening. Sales dynamics demonstrate how operating income offsets the costs of clinical product validation. Analyzing this chart helps identify asset undervaluation in a timely manner, which is critical for balancing the risks of an overheated business against capitalization.

Key competitors